MENU CLINICAL RESEARCH Cardea SOLO™ ECG is everything you need in a research ECG wearable. Cardea SOLO™ ECG For Clinical Research Cardea SOLO ECG is an all-inclusive wearable 7-day continuous cardiac monitoring system that will change the way you acquire and analyze ECG data for research. Collecting ECG Data Is As Simple As… Cardea SOLO Research Request Get more information on Cardea SOLO for your research project. Full Name* Email* Phone Company or Institution* How Did You Hear About Us? Referral Google/Search Engine Advertisement Big Pharma & Academic Institutions Turn To Cardea SOLO For ECG Data Collection FAST & EASY APPLICATION The friendly SOLO Sensor design made it an easy choice for Pharma clients. The SOLO Sensor is lightweight, water-resistant, and wire-free. Research participants could be mailed a sensor for self-application to enable social distancing. LOCAL & SECURE DATA The Cardea SOLO Analysis Software installs directly on your local PC and therefore your ECG data stays on your PC or private network — no transferring of data between your research team and a third party data analysis server. Get 100% access, 100% ECG data ownership, 100% of the time. Where You Can Find Cardea SOLO In Research Mobile Health Monitoring of Cardiac Status Abstract 14160: Assessment of Atrial Fibrillation Burden by Smartwatch Photoplethysmography Premature Atrial and Ventricular Contraction Detection Using Photoplethysmographic Data from a Smartwatch Nursing considerations of physical activity in AF ABOUT US Cardiac Insight, Inc. is a leading U.S. digital healthcare innovation company specializing in the development of medical-grade, body-worn ECG sensor technology and automated cardiac analysis solutions through its proprietary algorithms and software platforms. The company’s products include the Cardea SOLO™ wearable ECG Sensor and Software Analysis System as well as the Cardea 20/20 ECG™ – the only resting ECG System designed for cardiac risk screening in active youth and athletes at all levels of play. AFib is the most common type of treated heart arrhythmia, with an estimated 2.7 to 6.1 million people in the U.S. living with this arrhythmia. While AFib itself is typically not life-threatening, complications from AFib if left untreated include increased risk for heart problems and heart failure, and increased risk for stroke. AFib is responsible for about one in seven strokes. HOME ABOUT About Our Team News Events Blog Innovation with Impact PATIENTS CUSTOMERS Cardea SOLO Research VA / DOD PRODUCTS Cardea SOLO™ ECG System Cardea SOLO Reimbursement Cardea 20/20 ECG CONTACT US © 2021 Cardiac Insight Inc. All rights reserved. Privacy Policy Support by Seattle Web Design